Contineum Therapeutics, Inc. (CTNM) vs Kamada Ltd. (KMDA)
A side-by-side comparison of Contineum Therapeutics, Inc. and Kamada Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTNM
Contineum Therapeutics, Inc.
$12.30HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
KMDA
Kamada Ltd.
$7.99HealthcareDelayed quote: Oct 6, 2026, 10:04 AM EDT
Total return — CTNM vs KMDA
growth of $100 · dividends reinvested · last 2yCTNM -17.4% (-9.1%/yr)KMDA +62.5% (+27.5%/yr)KMDA compounded faster over this window
CTNM KMDA
CTNM vs KMDA: by the numbers
- •CTNM is the larger company ($463M vs $461M market cap).
- •KMDA is profitable (11.60% net margin) while CTNM runs a net loss (0.00%).
- •KMDA pays a dividend (5.25% yield), while CTNM has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | CTNM | KMDA |
|---|---|---|
| P/E ratio | N/A | 21.08 |
| Forward P/E | N/A | 16.73 |
| P/S ratio | N/A | 2.40 |
| P/B ratio | 1.93 | 1.71 |
| EV / EBITDA | N/A | 10.28 |
| FCF yield | N/A | 5.75% |
Profitability
| Metric | CTNM | KMDA |
|---|---|---|
| Gross margin | 0.00% | 40.82% |
| Operating margin | 0.00% | 14.51% |
| Net margin | 0.00% | 11.60% |
| ROE | -24.02% | 8.25% |
| ROIC | -27.22% | 6.95% |
Dividends
| Metric | CTNM | KMDA |
|---|---|---|
| Dividend yield | N/A | 5.25% |
| Payout ratio | N/A | 110.82% |
Growth (annualized)
| Metric | CTNM | KMDA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 10.59% |
| EPS CAGR (5Y) | N/A | -1.98% |
| FCF CAGR (5Y) | N/A | 40.37% |
| Total return CAGR (5Y) | N/A | 10.36% |
Frequently asked
- Does CTNM or KMDA pay a bigger dividend?
- KMDA pays a dividend (5.25% yield), while CTNM has no payments in the available dividend history.
- Is CTNM or KMDA more profitable?
- KMDA runs the higher net margin — CTNM at 0.00% versus KMDA at 11.60%.
Go deeper
Dig into the metrics
Kamada P/E ratioKamada dividend yieldContineum Therapeutics ROEKamada ROEContineum Therapeutics operating marginKamada operating marginContineum Therapeutics revenue growthKamada revenue growthContineum Therapeutics free cash flowKamada free cash flow
Contineum Therapeutics & Kamada appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.